Randomized Double--‐Blinded, Controlled Trial to Compare the Effectiveness of Sugammadex vs. Placebo to Prevent Residual Neuromuscular Block in the Post--‐Anesthesia Care Unit as Evaluated With a Non--‐Invasive Respiratory Volume Monitor
Phase of Trial: Phase IV
Latest Information Update: 24 Apr 2017
At a glance
- Drugs Sugammadex (Primary)
- Indications Neuromuscular blockade
- Focus Adverse reactions
- Acronyms Sugammadex
- 18 Apr 2017 Planned End Date changed from 1 Apr 2017 to 31 Dec 2017.
- 18 Apr 2017 Planned primary completion date changed from 1 Jan 2017 to 30 Jun 2017.
- 18 Apr 2017 Status changed from not yet recruiting to recruiting.